Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of SAR442970 in newly diagnosed type 1 diabetes
MOH_2025-02-18_013878Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Feb 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing SAR442970 with Placebo (2 arms). Primary endpoint: Change from baseline to week 26 in 2-hour mean C-peptide concentration during MMTT. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
brivekimig
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on MOH_2025-02-18_013878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-18_013878.